Lowest-Rated Stocks NASDAQ:ARCT Arcturus Therapeutics - ARCT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $20.81 +0.54 (+2.66%) (As of 01/31/2023 09:32 AM ET) Add Compare Share Share Today's Range$20.29▼$20.8750-Day Range$16.09▼$20.5952-Week Range$11.70▼$31.41Volume2,906 shsAverage Volume335,250 shsMarket Capitalization$552.71 millionP/E RatioN/ADividend YieldN/APrice Target$28.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcturus Therapeutics MarketRank™ ForecastAnalyst RatingHold2.13 Rating ScoreUpside/Downside39.4% Upside$28.25 Price TargetShort InterestHealthy7.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 2 Articles This WeekInsider TradingAcquiring Shares$39,996 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.93) to $0.89 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector104th out of 1,055 stocksPharmaceutical Preparations Industry37th out of 518 stocks 4.1 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 1 hold rating, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.25, Arcturus Therapeutics has a forecasted upside of 39.4% from its current price of $20.27.Amount of Analyst CoverageArcturus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.30% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 12.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 1.5 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcturus Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,996.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.70% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.74% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($5.93) to $0.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcturus Therapeutics (NASDAQ:ARCT) StockArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.Read More Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comArcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic FibrosisJanuary 24, 2023 | finanznachrichten.deCognitive Market Research: mRNA Vaccine Market to Reach $91.14 Billion by 2029January 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 24, 2023 | americanbankingnews.comAnalyzing Arcturus Therapeutics (NASDAQ:ARCT) & Lexaria Bioscience (NASDAQ:LEXX)January 15, 2023 | marketwatch.comCystic Fibrosis Drugs Market Size 2023 with Presentation Outlook, Horizontal Viewpoint, global ViewDecember 28, 2022 | finance.yahoo.comSwelling losses haven't held back gains for Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders since they're up 109% over 5 yearsDecember 19, 2022 | finance.yahoo.comArcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 15, 2022 | msn.comArcturus Therapeutics's Return On Capital Employed OverviewJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.December 13, 2022 | finance.yahoo.comArcturus Appoints John Markels, Ph.D. to its Board of DirectorsDecember 13, 2022 | marketwatch.commRNA Cancer Vaccines and Therapeutics Market 2022 Size, Share, Growth, Insights, Trends, and Forecasts 2027December 1, 2022 | finance.yahoo.comThe Founder of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Joseph Payne, Just Bought A Few More SharesNovember 29, 2022 | benzinga.comMassive Insider Trade At Arcturus TherapeuticsNovember 16, 2022 | finance.yahoo.comThese Analysts Just Made A Significant Downgrade To Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) EPS ForecastsNovember 12, 2022 | finance.yahoo.comArcturus Therapeutics Holdings Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | seekingalpha.comArcturus downgraded at Baird on delayed catalyst and uncertainties in CSL dealNovember 10, 2022 | seekingalpha.comArcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comArcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue EstimatesNovember 9, 2022 | finance.yahoo.comArcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline ProgressNovember 8, 2022 | finance.yahoo.comArcturus Therapeutics to Present at the Following Investor Conferences in NovemberNovember 4, 2022 | benzinga.comCitigroup Upgrades Arcturus Therapeutics to BuyNovember 4, 2022 | finance.yahoo.comArcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?November 3, 2022 | msn.comKymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue EstimatesNovember 2, 2022 | marketwatch.comArcturus Therapeutics Shares Rise 31% After Vaccine CollaborationNovember 2, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Arcturus TherapeuticsNovember 2, 2022 | markets.businessinsider.comWhere Arcturus Therapeutics Stands With AnalystsNovember 1, 2022 | reuters.comAustralia's CSL in mRNA vaccine licensing deal with ArcturusSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Company Calendar Last Earnings11/09/2022Today1/31/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees177Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.25 High Stock Price Forecast$44.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+35.8%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-203,670,000.00 Net Margins-284.78% Pretax Margin-284.78% Return on Equity-80.43% Return on Assets-42.96% Debt Debt-to-Equity Ratio0.22 Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual Sales$12.40 million Price / Sales44.57 Cash FlowN/A Price / Cash FlowN/A Book Value$8.66 per share Price / Book2.40Miscellaneous Outstanding Shares26,560,000Free Float23,183,000Market Cap$552.71 million OptionableOptionable Beta2.50 Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 51)Founder, Pres, CEO & Director Comp: $960kDr. Padmanabh Chivukula (Age 44)Founder, Chief Scientific Officer, COO & Sec. Comp: $750kMr. Andrew H. Sassine MBA (Age 59)CFO & Director Comp: $750kMr. Lance KurataChief Legal OfficerDr. Steven George Hughes M.B.A. (Age 55)M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board Comp: $644kMr. Keith C. Kummerfeld CPAVP of Fin. & Corp. ControllerDr. Dushyant B. Varshney Ph.D.Exec. VP & Chief Technology OfficerMr. Deepankar RoySr. Director of Investor RelationsKyle GutstadtSr. Analyst of Investor & PRMr. Kevin T. SkolSr. VP of Bus. Devel. & Alliance ManagementMore ExecutivesKey CompetitorsRepare TherapeuticsNASDAQ:RPTXAVEO PharmaceuticalsNASDAQ:AVEOSIGA TechnologiesNASDAQ:SIGAI-MabNASDAQ:IMABNuvation BioNYSE:NUVBView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 10,355 shares on 1/30/2023Ownership: 5.456%Byrne Asset Management LLCBought 1,995 shares on 1/30/2023Ownership: 0.025%ARK Investment Management LLCSold 169,274 shares on 1/24/2023Ownership: 7.578%Bank Julius Baer & Co. Ltd ZurichBought 6,707 shares on 1/24/2023Ownership: 0.250%Allspring Global Investments Holdings LLCBought 673 shares on 1/23/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ARCT Stock - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price forecast for 2023? 8 Wall Street analysts have issued 1 year target prices for Arcturus Therapeutics' stock. Their ARCT share price forecasts range from $14.00 to $44.00. On average, they expect the company's stock price to reach $28.25 in the next year. This suggests a possible upside of 39.4% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2023? Arcturus Therapeutics' stock was trading at $16.96 on January 1st, 2023. Since then, ARCT stock has increased by 19.5% and is now trading at $20.27. View the best growth stocks for 2023 here. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Wednesday, November, 9th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.01) by $0.68. The biotechnology company earned $13.37 million during the quarter, compared to analyst estimates of $3.50 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 80.43% and a negative net margin of 284.78%. What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and What is Arcturus Therapeutics' stock symbol? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT." Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (7.58%), Sumitomo Mitsui Trust Holdings Inc. (5.46%), Hennion & Walsh Asset Management Inc. (0.25%), Bank Julius Baer & Co. Ltd Zurich (0.25%), Byrne Asset Management LLC (0.02%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcturus Therapeutics' stock price today? One share of ARCT stock can currently be purchased for approximately $20.27. How much money does Arcturus Therapeutics make? Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $538.37 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,670,000.00 in net income (profit) each year or ($5.56) on an earnings per share basis. How many employees does Arcturus Therapeutics have? The company employs 177 workers across the globe. How can I contact Arcturus Therapeutics? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com. This page (NASDAQ:ARCT) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.